Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 study

•TREM-1 engagement activates myeloid cells and worsens cardiac remodeling in experimental acute myocardial infarction (AMI).•High plasma levels of soluble TREM-1 associate with higher risk of recurrent major adverse cardiac events in AMI patients.•Common TREM1 genetic variants are associated with sTREM-1 levels in AMI patients and explain ~4% of its total variance.•Further studies on MI patients are needed to assess the relationship between TREM1 genetic variants and outcome.